Table 3.
Overall survival and disease-free survival
| Trial | Treatment | N | Overall survival |
Disease-free survival |
||
|---|---|---|---|---|---|---|
| Median OS (95% CI) (months) | Hazard ratio (95% CI) | Median DFS (95% CI) (months) | Hazard ratio (95% CI) | |||
| Primrose 2014 | FOLFOX/Surgery/FOLFOX | 128 | NM | – | 20.5 (16.8–26.7) | – |
| FOLFOX + CET/Surgery/FOLFOX + CET | 129 | 39.1 (23.6-NM) | 1.49 (0.86–2.60) p = 0.16 | 14.1 (11.8–15.9) | 1.48 (1.04–2.12) p = 0.03 | |
| Nordlinger 2013 (Randomised) | Surgery | 182 | 54.3 (41.9–79.4) | – | 12.5 (9.7–17.7) | – |
| FOLFOX/Surgery/FOLFOX | 182 | 61.3 (51.0–83.4) | 0.88 (0.68–1.14) p = 0.34 | 20.0 (15.9–27.6) | 0.81 (0.64–1.02) p = 0.07 | |
| Nordlinger 2013 (Eligible) | Surgery | 171 | 55.0 (41.9–79.4) | – | 12.5 (9.7–18.2) | – |
| FOLFOX/Surgery/FOLFOX | 171 | 63.7 (52.7–87.3) | 0.87 (0.66–1.14) p = 0.30 | 20.9 (17.1–28.9) | 0.78 (0.61–0.99) p = 0.04 | |
| Ychou 2009 | Surgery/FUFA | 153 | NR | – | 21.6 (14.6–30.4) | – |
| Surgery/FOLFIRI | 153 | NR | 1.09 (0.72–1.64) p = 0.69* | 24.7 (18.7–38.9) | 0.89 (0.66–1.19) p = 0.44* | |
| Portier 2006 | Surgery | 85 | 46.4 (37.4–55.4) | – | 17.6 (12.3–22.9) | – |
| Surgery/FUFA | 86 | 62.1 (41.1–83.1) | 0.73 (0.48–1.10) p = 0.13* | 24.4 (17.3–31.5) | 0.66 (0.46–0.96) p = 0.03* | |
Abbreviations: CI, confidence interval; DFS, disease-free survival; NA, not applicable; NM, not met; NR, not reported; OS, overall survival. * From multivariable analysis correcting for other prognostic factors.